TW200611693A - GPR35 and modulators thereof for the treatment of metabolic-related disorders - Google Patents

GPR35 and modulators thereof for the treatment of metabolic-related disorders

Info

Publication number
TW200611693A
TW200611693A TW094116911A TW94116911A TW200611693A TW 200611693 A TW200611693 A TW 200611693A TW 094116911 A TW094116911 A TW 094116911A TW 94116911 A TW94116911 A TW 94116911A TW 200611693 A TW200611693 A TW 200611693A
Authority
TW
Taiwan
Prior art keywords
gpr35
compound
alkoxy
metabolic
metabolic stabilizing
Prior art date
Application number
TW094116911A
Other languages
English (en)
Inventor
James N Leonard
Zhi-Liang Chu
David J Unett
Joel E Gatlin
Ibragim Gaidarov
Jun Qiu
Philip J Skinner
P Douglas Boatman
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of TW200611693A publication Critical patent/TW200611693A/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
TW094116911A 2004-05-26 2005-05-24 GPR35 and modulators thereof for the treatment of metabolic-related disorders TW200611693A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57484904P 2004-05-26 2004-05-26
US58515604P 2004-07-01 2004-07-01
US61286204P 2004-09-24 2004-09-24
US64468405P 2005-01-18 2005-01-18
US64796905P 2005-01-27 2005-01-27

Publications (1)

Publication Number Publication Date
TW200611693A true TW200611693A (en) 2006-04-16

Family

ID=35207528

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094116911A TW200611693A (en) 2004-05-26 2005-05-24 GPR35 and modulators thereof for the treatment of metabolic-related disorders

Country Status (3)

Country Link
US (2) US8039219B2 (zh)
TW (1) TW200611693A (zh)
WO (1) WO2005119252A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9040583B2 (en) 2009-07-22 2015-05-26 Temple University-Of The Commonwealth System Of Higher Education Treatment of disorders associated with G protein-coupled receptor 35 (GPR35)
US20120022116A1 (en) * 2010-07-20 2012-01-26 Huayun Deng Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
CA2840516A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
WO2013022740A2 (en) * 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof
MX2016004032A (es) * 2013-09-30 2016-06-02 Univ California Identificacion de cxcr8, un receptor de quimiocinas novedoso.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NZ248573A (en) * 1992-09-10 1996-02-27 Lilly Co Eli 5-arylmethyl (and methylidene) thiazolidin-4-one derivatives; their preparation and pharmaceutical compositions
JPH0770095A (ja) * 1993-09-03 1995-03-14 Ono Pharmaceut Co Ltd ロダニン誘導体
US7119190B2 (en) * 1997-04-14 2006-10-10 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
JP2002517222A (ja) * 1998-06-11 2002-06-18 スミスクライン ビーチャム コーポレーション Ｇｐｒ３５ａ受容体
WO2000023603A2 (en) * 1998-10-21 2000-04-27 Arch Development Corporation Methods of treatment of type 2 diabetes

Also Published As

Publication number Publication date
WO2005119252A2 (en) 2005-12-15
US20070077602A1 (en) 2007-04-05
US8039219B2 (en) 2011-10-18
US20120208843A1 (en) 2012-08-16
WO2005119252A3 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
GB0112348D0 (en) Compounds
TW200626553A (en) Novel compounds
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
TW200745122A (en) New compounds I
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
ATE433450T1 (de) Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
TW200634001A (en) Novel compounds
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders
MX2007003119A (es) Nuevas amidas heterociclicas.
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament
TW200745133A (en) New compounds II
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
HK1106246A1 (en) S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s-
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands